ERBB2 and breast cancer: In this study, we examine outcomes of women with early stage, node-negative HER2+ breast cancer treated with single (NCDB surrogate for taxane/trastuzumab) or multi-agent NAC and the association between treatment, pCR, and survival using a large national database.